Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Epizyme Inc
(NQ:
EPZM
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 11, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Epizyme Inc
< Previous
1
2
3
4
5
Next >
Epizyme: Q2 Earnings Insights
August 09, 2022
Epizyme (NASDAQ:EPZM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
Epizyme, Inc.
Via
Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
July 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
June 27, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Why Is Epizyme (EPZM) Stock Up 75% Today?
June 27, 2022
EPZM stock is jumping higher today on news that Epizyme is being acquired by French pharmaceutical company Ipsen.
Via
InvestorPlace
Why Epizyme Shares Are Soaring Today
June 27, 2022
Epizyme Inc (NASDAQ: EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022
June 28, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
June 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
June 28, 2022
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...
Via
FinancialNewsMedia
Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal
June 27, 2022
Axsome Therapeutics (AXSM) stock is rising higher on Monday following an update from the FDA about product labeling for one of its drugs.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
June 27, 2022
Upgrades
Via
Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
June 28, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
June 27, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
June 27, 2022
From
Halper Sadeh LLP
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 27, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 27, 2022
Good morning, trader! We're starting off the week with an overview of the biggest pre-market stock movers for Monday morning!
Via
InvestorPlace
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
June 27, 2022
Ipsen SA (OTC: IPSEY) has
Via
Benzinga
Epizyme + 20 Stocks Moving In Monday's Pre-Market Session
June 27, 2022
Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday.
Via
Benzinga
Ipsen to acquire Epizyme, expanding its portfolio in oncology
June 27, 2022
From
Epizyme, Inc.
Via
Business Wire
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
June 23, 2022
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
June 22, 2022
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Via
Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
June 14, 2022
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 48.5% to $2.57 in pre-market trading after the company reached an agreement with Phillip Morris for international electronic nicotine...
Via
Benzinga
93 Biggest Movers From Yesterday
June 14, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...
Via
Benzinga
91 Biggest Movers From Friday
June 13, 2022
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Via
Benzinga
44 Stocks Moving In Friday's Mid-Day Session
June 10, 2022
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Via
Benzinga
25 Stocks Moving in Friday's Pre-Market Session
June 10, 2022
Gainers Regis Corporation (NYSE: RGS) rose 74.4% to $0.9753 in pre-market trading. Regis partnered with salon technology provider Zenoti to support its 5,000+ locations.
Via
Benzinga
Epizyme's Return On Capital Employed Insights
June 09, 2022
Epizyme (NASDAQ:EPZM) brought in sales totaling $8.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.58%, resulting in a loss of $55.51 million.
Via
Benzinga
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
June 02, 2022
From
Epizyme, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Epizyme To Participate in H.C. Wainwright Global Investment Conference
May 17, 2022
From
Epizyme, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.